Vyndaqel Market, By Indication (Wild-type transthyretin-mediated amyloidosis cardiomyopathy (ATTR-CM, wild-type), Hereditary transthyretin-mediated amyloidosis cardiomyopathy (ATTR-CM, variant), and Transthyretin-mediated amyloidosis polyneuropathy (ATTR-PN/FAP) ), By Strength ( 20 mg and 61 mg), By Payer (Public, Private, and Self-pay/Out-of-pocket), By Distribution Channel ( Hospital pharmacies, Specialty/Online pharmacies, and Retail pharmacies), By End User ( Hospitals, Cardiac Amyloidosis Centers, Ambulatory Surgical Centers, and Homecare Settings), By Age group ( Adults (≥18 yrs) and Elderly (≥65 yrs)), By Geography (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa) - Growth Trends and Forecasts (2025-2032)
Select a License Type that Suits your Business Needs
US$ 2,000
Two thousand dollars
Single User License
(1 User)
US$ 4,500
US$ 3,000
Three thousand dollars
Frequently Purchased
Multi User License
(Upto 7 Users)
US$ 7,000
US$ 5,000
Five thousand dollars
Corporate User License
(Unlimited Users)
US$ 10,000
US$ 6,000
Six thousand dollars
Client Testimonials
Client Testimonials
Our Clients
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
Credibility and Certifications
Trusted Insights, Certified Excellence! Coherent Market Insights is a certified data advisory and business consulting firm recognized by global institutes.

860519526
9001:2015
27001:2022